Drugs / Vudalimab
Vudalimab
Trials 9
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2024-02-27 | Xencor, Inc. | Results Xencor Reports Fourth Quarter and Full Year 2023 Financial Results xencor.com ↗
The Company also presented encouraging early clinical data from its Phase 2 study of vudalimab monotherapy for patients with clinically defined high-risk metastatic castration-resistant prostate cancer (mCRPC). |
| 2022-11-10 | Xencor, Inc. | Results Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting xencor.com ↗
Though we observed clinical activity, including multiple PSA50 responses and a partial response even in this small number of patients with advanced mCRPC, tolerability was a concern, so we are de-intensifying the chemotherapy regimen and maintaining the vudalimab dose. |
| 2021-11-12 | Xencor, Inc. | Results Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting xencor.com ↗
A complete response was observed in a patient with BRCA1+ high-grade serous ovarian cancer, who had received multiple prior treatments, including olaparib and nivolumab in the metastatic setting. |
| 2020-11-09 | Xencor, Inc. | Results Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting xencor.com ↗
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 9, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported data from its ongoing Phase 1 study evaluating XmAb ® 20717, a PD-1 x CTLA-4 bispecific antibody and Xencor’s first tumor microenvironment activator, in patients with advanced solid tumors (DUET-2). |
| 2020-05-13 | Xencor, Inc. | Results Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors xencor.com ↗
In our first six dose-escalation cohorts, we observed XmAb20717 to be generally well-tolerated in heavily pretreated patients with advanced solid tumors. |
| 2017-11-08 | Xencor, Inc. | Results Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting xencor.com ↗
Data suggest that clinical development is warranted for the treatment of human malignancies |
| 2016-11-11 | Xencor, Inc. | Results Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and Additional Bispecific Antibody Candidates at Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting xencor.com ↗
Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that data from preclinical studies on XmAb®20717, a PD-1 x CTLA-4 dual checkpoint inhibitor, and additional bispecific antibody candidates will be presented during presentations at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting taking place November 9-13, 2016 . |
All press releases naming this drug 10 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vudalimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06173505 ↗ |
| Known as | XmAb2071 | “To evaluate the antineoplastic efficacy of vudalimab (XmAb2071) in anaplastic thyroid cancer, as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.” NCT05453799 ↗ |
| Known as | XmAb20717 | “A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies” NCT05032040 ↗ |
| Action | Inhibit | “vudalimab, an anti-PD-1/CTLA-4 bispecific antibody” NCT06173505 ↗ |
| Modality | Monoclonal antibody | “Monoclonal bispecific antibody” NCT03517488 ↗ |
| Route | Intravenous | “administered by intravenous dosing” NCT03517488 ↗ |